Piramal Pharma Solutions, a contract development and manufacturing organisation, has announced an $80m investment to expand ...

Till 12:35 pm; a combined 32.3 million shares representing 2.43 per cent of total equity of PPL changed hands on the NSE and BSE.

Piramal Pharma on Thursday reported over four ... the company has announced a $80 million expansion plan at the Lexington facility which is expected to be completed by the FY27 end, she added.

Earlier this month, Piramal Pharma announced that it would invest $80 million (about ₹670 crore) in expanding its Lexington facility in Kentucky, United States.

Piramal Pharma is utilising a capex of about $85 million for various initiatives, including capacity expansion, maintenance and de-bottlenecking of CDMO sites, in the current fiscal, according to its ...

Piramal Pharma (PIRPHARM) delivered better-than-expected operational performance in 2QFY25 fueled by superior traction in the CDMO segment (59% of sales). Following earnings deterioration in FY23 ...

Piramal Enterprises Q2 Results Live : Piramal Enterprises declared their Q2 results on 23 Oct, 2024, showcasing a remarkable performance with a topline increase of 15.38% year-over-year (YoY) and ...

Piramal Pharma's tax expenses also rose threefold in the span of a year. In the previous fiscal cycle, the pharma company earmarked a total of Rs 19.03 crore for its tax expenses. Come September ...

Piramal Pharma's company's revenue for the quarter under review stood at Rs 2,242 crore as compared to Rs 1,911 crore which implies an increase of 17 per cent Y-o-Y ...

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global ...